Cipher Pharmaceuticals, Inc. (CPH.TO)
14.10
0.00 (0.00%)
CAD |
TSX |
Aug 24, 16:00
Cipher Pharmaceuticals Gross Profit Margin (Quarterly) : 65.58% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 65.58% |
| March 31, 2026 | 67.89% |
| December 31, 2025 | 66.36% |
| September 30, 2025 | 67.70% |
| June 30, 2025 | 67.83% |
| March 31, 2025 | 60.89% |
| December 31, 2024 | 43.83% |
| September 30, 2024 | 62.44% |
| June 30, 2024 | 73.64% |
| March 31, 2024 | 77.09% |
| December 31, 2023 | 75.04% |
| September 30, 2023 | 77.83% |
| June 30, 2023 | 73.47% |
| March 31, 2023 | 72.98% |
| December 31, 2022 | 80.93% |
| September 30, 2022 | 82.05% |
| June 30, 2022 | 78.32% |
| March 31, 2022 | 76.79% |
| December 31, 2021 | 81.80% |
| September 30, 2021 | 79.53% |
| June 30, 2021 | 80.86% |
| March 31, 2021 | 80.65% |
| December 31, 2020 | 83.02% |
| September 30, 2020 | 81.42% |
| June 30, 2020 | 79.86% |
| Date | Value |
|---|---|
| March 31, 2020 | 81.56% |
| December 31, 2019 | 82.55% |
| September 30, 2019 | 83.75% |
| June 30, 2019 | 83.38% |
| March 31, 2019 | 83.36% |
| December 31, 2018 | 85.22% |
| September 30, 2018 | 84.57% |
| June 30, 2018 | 89.54% |
| March 31, 2018 | 84.21% |
| December 31, 2017 | 93.44% |
| September 30, 2017 | 93.17% |
| June 30, 2017 | 92.97% |
| March 31, 2017 | 91.43% |
| December 31, 2016 | 83.76% |
| September 30, 2016 | 92.29% |
| June 30, 2016 | 95.69% |
| March 31, 2016 | 92.06% |
| December 31, 2015 | 76.41% |
| September 30, 2015 | 73.91% |
| June 30, 2015 | 75.50% |
| March 31, 2015 | 95.63% |
| December 31, 2014 | 95.64% |
| September 30, 2014 | 95.51% |
| June 30, 2014 | 96.13% |
| March 31, 2014 | 96.32% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| HLS Therapeutics, Inc. | 42.90% |
| Bausch Health Cos., Inc. | 65.04% |
| BioSyent, Inc. | 65.02% |
| Revive Therapeutics Ltd. | -- |
| Knight Therapeutics, Inc. | 38.94% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 23.32% |
| Return on Assets | 18.86% |
| Return on Invested Capital | 21.75% |
| Profit Margin (Quarterly) | 33.26% |
| Operating Margin (Quarterly) | 37.08% |
| Return on Net Operating Assets | 26.59% |